Effects of Hypericum perforatum and paroxetine on rat performance in the elevated T-maze

Pharmacological Research

Volumn 48, Issue 2, 2003, Pages 199-207

  Beijamini, Venessa ^a   Andreatini, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Animal model; Antidepressant; Anxiety; Forced swim; Panic; Paroxetine; Phytotherapy

Indexed keywords

HYPERICUM PERFORATUM EXTRACT; PAROXETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; FORCED SWIMMING TEST; GENERALIZED ANXIETY DISORDER; MALE; MAZE TEST; NONHUMAN; OPEN FIELD BEHAVIOR; PANIC; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

EID: 0038544570     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00097-5     Document Type: Article

References (51)

1. Graeff F.G., Viana M.B., Tomaz C. The elevated T-maze, a new experimental model of anxiety and memory: effect of diazepam. Braz. J. Med. Biol. Res. 26:1993;67-70.
2. Viana M.B., Tomaz C., Graeff F.G. The elevated T-maze: a new animal model of anxiety and memory. Pharmacol. Biochem. Behav. 49:1994;549-554.
3. Zangrossi H., Graeff F.G. Behavioral validation of the elevated T-maze, a new animal model of anxiety. Brain Res. Bull. 44:1997;1-5.
4. Graeff F.G., Ferreiro Netto C., Zangrossi H. Jr. The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev. 23:1998;237-246.
5. Custódio Teixeira R.C., Zangrossi H. Jr., Graeff F.G. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol. Biochem. Behav. 65:2000;571-576.
6. Argyropoulos S.V., Sandford J.J., Nutt D.J. The psychobiology of anxiolytic drugs. Part 2. Pharmacological treatments of anxiety. Pharmacol. Ther. 88:2000;213-227.
7. Deakin J.F.W., Graeff F.G. 5-HT and mechanisms of defense. J. Psychopharmacol. 5:1991;305-315.
8. Kasper S. Hypericum perforatum - a review of clinical studies. Pharmacopsychiatry. 34(Suppl. 1):2001;S51-S55.
9. Linde K., Ramirez G., Murlow C.D., Pauls A., Weidenhammer W., Melchart D. St. John's Wort for depression - an overview and meta-analysis of randomized clinical trials. Br. Med. J. 313:1996;253-258.
10. Kim H.L., Streltzer J., Goebert D. St. John's Wort for depression: a meta-analysis of well-defined clinical trials. J. Nerv. Ment. Dis. 187:1999;532-539.
11. Linde K, Mulrow CD. St. John's Wort for depression (Cochrane Review). The Cochrane library, No. 1. Oxford: Update Software; 2001.
12. Di Carlo G., Borrelli F., Ernest E., Izzo A.A. St. John's Wort: prozac from the plant kingdom. Trends Pharmacol. Sci. 22:2001;292-297.
13. Shelton R.C., Keller M.B., Gelemberg A., Dunner D.L., Hirschfeld R., Thase M.E.et al. Effectiveness of St. John's Wort in major depression: a randomised controlled trial. JAMA. 285:2001;1978-1986.
14. Gambarana C., Ghiglieri O., Tolu P., De Montis M.G., Giachetti D., Bombardelli E.et al. Efficacy of a H. perforatum (St. John's Wort) extract in preventing and reverting a condition of escape deficit in rats. Neuropsychopharmacology. 21:1999;247-257.
15. Butterweck V., Wall A., Liefländer-Wulf U., Winterhoff H., Nahstedt A. Effects of total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry. 30:1997;117-124.
16. Chatterjee S.S., Bhattacharya S.K., Wonnemann M., Singer A., Müller W.E. Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci. 63:1998;499-510.
17. Muller W.E., Singer A., Wonnemann M., Hafner U., Rolli M., Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry. 3(Suppl. 1):1998;16-21.
18. Wonneman M., Singer A., Siebert B., Muller W.E. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's Wort. Pharmacopsychiatry. 34(Suppl. 1):2001;S148-S151.
19. Muller W.E., Rolli M., Hafner U. The effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 30:1997;102-107.
20. Yager J., Susan L., Siegfreid M.D., Di Matteo T.L. Use of alternative remedies by psychiatric patients: illustrative vignettes and a discussion of the issues. Am. J. Psychiatr. 156:1999;1432-1438.
21. Davison J.R.T., Connor K.M. St. John's Wort in generalized anxiety disorder: three case reports. J. Clin. Psychopharmacol. 21:2001;635-636.
22. Taylor L.H., Kobak K.A. An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. J. Clin. Psychiatr. 61:2000;575-578.
23. Stevinson C., Dixon M., Ernst E. Hypericum for fatigue - a pilot study. Phytomedicine. 5:1998;443-447.
24. Coleta M., Campos M.G., Cotrim M.D., Proença da Cunha A. Comparative evaluation of Melissa officinalis L., Tilia europaea, Passiflora edulis Sims. and Hypericum perforatum L. in the elevated plus maze anxiety test. Pharmacopsychiatry. 34(Suppl. 1):2001;S20-S21.
25. Chatterjee S.S., Noldner E., Koch E., Erdelmeier C. Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry. 31(Suppl. 1):1998;7-15.
26. Vanderbogaerde A., Zanoli P., Puia G., Truzzi C., Kamuhabwa A., De Witte P.et al. Evidence that total extract of Hypericum perforatum affects exploratory behavior and exerts anxiolytic effects in rats. Pharmacol. Biochem. Behav. 65:2000;627-633.
27. Flausino O.A. Jr., Zangrossi H. Jr., Salgado J.V., Viana M.B. Effects of acute and chronic treatment with Hypericum perforatum L. (LI 160) on different anxiety-related responses in rats. Pharmacol. Biochem. Behav. 71:2002;259-265.
28. Kumar V., Jaiswal A.K., Singh P.N., Bhattacharya S.K. Anxiolytic activity of Indian Hypericum perforatum Linn: an experimental study. Indian J. Exp. Biol. 38:2000;36-41.
29. Beijamini V., Andreatini R. Effects of Hypericum perforatum and paroxetine in the Mouse Defense Test Battery. Pharmacol Biochem Behav. 74:2003;1015-1024.
30. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47:1978;379-391.
31. Beijamini V., Skalisz L.L., Joca S.R.L., Andreatini R. The effect of oxcarbazepine on behavioural despair and learned helplessness. Eur. J. Pharmacol. 347:1998;23-27.
32. Kelly AE. Locomotor activity and exploration. In: Sahgal A, editor. Behavioural neuroscience: a practical approach, vol. II. Oxford: Oxford University Press; 1993. p. 1-21.
33. Butterweck V., Petereit F., Winterhoff H., Nahstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med. 64:1998;291-294.
34. De Vry J., Maurel S., Schreiber R., de Beun R., Jentzsch K.R. Comparison of Hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. Eur. Neuropsychopharmacol. 9:1999;461-468.
35. Panocka I., Perfumi M., Angeletti S., Ciccopioppo R., Massi M. Effects of Hypericum perforatum extract on ethanol intake, and on behavioral despair: a search for the neurochemical systems involved. Pharmacol. Biochem. Behav. 66(1):2000;105-111.
36. Hascoet M., Bourin M., Colombel M.C., Fiocco A.J., Baker G.B. Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol. Biochem. Behav. 65:2000;339-344.
37. Hascoet M., Bourin M., Dhonnchadha B.A.N. The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four-plate test. Pharmacol. Biochem. Behav. 67:2000;44-53.
38. Winslow J.T., Insel T.R. Serotonergic and catecholinergic reuptake inhibitors have opposite effects on the ultrasonic isolation calls of rat pups. Neuropsychopharmacology. 3:1990;51-59.
39. Schreiber R., Melon C., De Vry J. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology. 135:1998;383-931.
40. Lightowler S., Kennet G.A., Williamson I.J.R., Blackburn T.P., Tulloch I.F. Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacolol. Biochem. Behav. 49:1994;281-285.
41. Duxon M.S., Starr K.R., Upton N. Latency to paroxetine-induced anxiolysis in the rat is reduced by co-adminsitration of the 5-HT1A receptor antagonist WAY100635. Br. J. Pharmacol. 130:2000;1713-1719.
42. 3H ]-ketanserin binding and an anxiolytic profile in the elevated x-maze Br. J. Pharmacol. 107:1992;108.
43. Sanchez C., Meier E. Behavioral profiles of SSRIs in animal models of depression. Are they all alike? Psychopharmacology. 129:1997;197-205.
44. Koks S., Beljajev S., Koovit I., Abramov U., Bourin M., Vasar E. 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology. 153:2001;365-372.
45. Koks S., Bourin M., Vöikar V., Soosaar A., Vasar E. Role of CCK in anti-exploratory action of paroxetine, 5-HT reuptake inhibitor. Int. J. Neuropsychopharmacol. 2:1999;9-16.
46. Rocca P., Fonzo V., Scotta M., Zanalda E., Ravizza L. Paroxetine efficacy in the treatment of generalised anxiety disorder. Acta Psychiatr. Scand. 95:1997;444-450.
47. Allgulander C., Cloninger C.R., Przybeck T.R., Brandt L. Changes on the temperament and character inventory after paroxetine treatment in volunteers with generalised anxiety disorder. Psychopharmacol. Bull. 34:1998;165-166.
48. Bhattacharya S.K., Chakrabarti A., Chatterjee S.S. Activity profiles of two hyperforin-containing Hypericum extracts in behavioural models. Pharmacopsychiatry. 31(Suppl. 1):1998;22-29.
49. Ballenger J.C., Wheadon D.E., Steiner M., Bushnell W., Gergel I.P. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am. J. Psychiatr. 155:1998;36-42.
50. Lecrubier Y., Bakker A., Dunbar G., Judge R. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr. Scand. 95:1997;145-152.
51. Lecrubier Y., Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr. Scand. 95:1997;153-160.